Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1996 1
1998 18
1999 7
2000 11
2001 16
2002 30
2003 40
2004 43
2005 37
2006 58
2007 36
2008 42
2009 38
2010 34
2011 36
2012 24
2013 23
2014 24
2015 29
2016 22
2017 15
2018 11
2019 16
2020 12
2021 18
2022 8
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

599 results
Results by year
Filters applied: . Clear all
Page 1
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB. Brown AJH, et al. Cell. 2021 Nov 24;184(24):5886-5901.e22. doi: 10.1016/j.cell.2021.11.001. Cell. 2021. PMID: 34822784 Free article. Clinical Trial.
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. ...Through this approach, we rationally d …
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acety …
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from …
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate o …
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. Knapp M, et al. Int J Geriatr Psychiatry. 2017 Dec;32(12):1205-1216. doi: 10.1002/gps.4583. Epub 2016 Oct 13. Int J Geriatr Psychiatry. 2017. PMID: 27739182 Free PMC article. Clinical Trial.
We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients. ...A total of 295 community-dwelling patients with moderate/severe Alzheimer's disease, already treat …
We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzhe …
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Bago Rožanković P, et al. Cogn Behav Neurol. 2021 Dec 2;34(4):288-294. doi: 10.1097/WNN.0000000000000285. Cogn Behav Neurol. 2021. PMID: 34851866 Clinical Trial.
OBJECTIVE: To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. METHOD: We conducted a prospective, randomized, 6-month clinical trial involving 85 individuals with moderate AD divided into two groups: group 1 (n = 42) was t …
OBJECTIVE: To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. METHOD: We conducted …
Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.
Devanand DP, Pelton GH, D'Antonio K, Ciarleglio A, Scodes J, Andrews H, Lunsford J, Beyer JL, Petrella JR, Sneed J, Ciovacco M, Doraiswamy PM. Devanand DP, et al. Am J Geriatr Psychiatry. 2018 Oct;26(10):1050-1060. doi: 10.1016/j.jagp.2018.05.008. Epub 2018 Jun 28. Am J Geriatr Psychiatry. 2018. PMID: 30037778 Free PMC article. Clinical Trial.
In the randomized trial, there were no treatment group differences between donepezil and placebo on dementia conversion rates, ADAS-Cog, SRT total immediate recall, or FAQ. Neither baseline cognitive impairment severity nor apolipoprotein E e4 genotype influenced donepe …
In the randomized trial, there were no treatment group differences between donepezil and placebo on dementia conversion rates, ADAS-C …
Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.
Jia Y, Zhang X, Yu J, Han J, Yu T, Shi J, Zhao L, Nie K. Jia Y, et al. BMC Complement Altern Med. 2017 Dec 29;17(1):556. doi: 10.1186/s12906-017-2064-x. BMC Complement Altern Med. 2017. PMID: 29284465 Free PMC article. Clinical Trial.
Patients with mild to moderate AD meeting the included criteria were randomly allocated into either acupuncture or donepezil hydrochloride groups. The acupuncture group(AG) was given acupuncture treatment three times per week and the donepezil hydrochloride group(DG …
Patients with mild to moderate AD meeting the included criteria were randomly allocated into either acupuncture or donepezil hydrochl …
Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial.
Shi J, Wei M, Ni J, Sun F, Sun L, Wang J, Yu T, Wang K, Lv P, Wang Y, Zhang Y, Gao X, Gao X, Luo B, Mao S, Zhang B, Ren X, Yu F, Hu W, Yin P, Wu N, Liu X, Bi Q, Wang Y, Tian J; CHASE Study Group. Shi J, et al. J Transl Med. 2020 Feb 13;18(1):76. doi: 10.1186/s12967-020-02232-z. J Transl Med. 2020. PMID: 32054507 Free PMC article. Clinical Trial.
METHODS: A 24-week RCT was conducted in 16 centres. Participants were grouped into TZ, donepezil or placebo. The co-primary outcomes were the Vascular Dementia Assessment Scale-cognitive subscale (VADAS-cog) and Clinician's Interview-based Impression of Change-plus …
METHODS: A 24-week RCT was conducted in 16 centres. Participants were grouped into TZ, donepezil or placebo. The co-primary outcomes …
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.
Campbell NL, Perkins AJ, Gao S, Skaar TC, Li L, Hendrie HC, Fowler N, Callahan CM, Boustani MA. Campbell NL, et al. J Am Geriatr Soc. 2017 Jul;65(7):1497-1504. doi: 10.1111/jgs.14827. Epub 2017 Mar 14. J Am Geriatr Soc. 2017. PMID: 28295141 Free PMC article. Clinical Trial.
Our objective was to determine if differences in rates of adherence and tolerability exist among new users to acetylcholinesterase inhibitors (AChEI's). DESIGN: Pragmatic randomized, open label comparative trial of AChEI's currently available in the United States. . …
Our objective was to determine if differences in rates of adherence and tolerability exist among new users to acetylcholinesterase inhibitor …
Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.
Fang X, Zhang J, Zhao J, Wang L. Fang X, et al. J Healthc Eng. 2022 Mar 25;2022:9148650. doi: 10.1155/2022/9148650. eCollection 2022. J Healthc Eng. 2022. PMID: 35368930 Free PMC article. Retracted. Clinical Trial.
OBJECTIVE: To explore the effect of resveratrol (RES) combined with donepezil hydrochloride on inflammatory factor level and cognitive function level of patients with Alzheimer's disease (AD). METHODS: A total of 90 AD patients treated in our hospital from June 2019 …
OBJECTIVE: To explore the effect of resveratrol (RES) combined with donepezil hydrochloride on inflammatory factor level and cognitiv …
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA).
Shim Y, Han HJ, Park KW, Kim BC, Park KH, Park MY, Kim HJ, Moon SY, Choi SH, Park KW, Yang DW, Yoon SJ, Kim SY, Youn YC, Choi H, Yoon KE, Cho HJ, Han SH. Shim Y, et al. J Alzheimers Dis. 2022;87(1):391-403. doi: 10.3233/JAD-215277. J Alzheimers Dis. 2022. PMID: 35275529 Clinical Trial.
BACKGROUND: Preclinical studies in transgenic models of Alzheimer's disease (AD) suggest that DHP1401 has neuroprotective and memory-enhancing effects. ...However, in the subgroup with mild AD patients (MMSE, 20-26) who received the high dose of DHP1401 and the group that …
BACKGROUND: Preclinical studies in transgenic models of Alzheimer's disease (AD) suggest that DHP1401 has neuroprotective and memory- …
599 results